X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs ABBOTT INDIA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD ABBOTT INDIA ORCHID PHARMA LTD/
ABBOTT INDIA
 
P/E (TTM) x -0.1 36.8 - View Chart
P/BV x 0.1 9.5 1.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ORCHID PHARMA LTD   ABBOTT INDIA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
ABBOTT INDIA
Mar-18
ORCHID PHARMA LTD/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1946,110 3.2%   
Low Rs353,996 0.9%   
Sales per share (Unadj.) Rs276.51,552.2 17.8%  
Earnings per share (Unadj.) Rs-79.2188.8 -42.0%  
Cash flow per share (Unadj.) Rs-43.5196.4 -22.1%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs53.9796.6 6.8%  
Shares outstanding (eoy) m70.4521.25 331.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.3 12.7%   
Avg P/E ratio x-1.426.8 -5.4%  
P/CF ratio (eoy) x-2.625.7 -10.2%  
Price / Book Value ratio x2.16.3 33.5%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m8,067107,376 7.5%   
No. of employees `0002.83.3 84.3%   
Total wages/salary Rs m2,5273,937 64.2%   
Avg. sales/employee Rs Th6,956.19,929.3 70.1%   
Avg. wages/employee Rs Th902.51,185.1 76.2%   
Avg. net profit/employee Rs Th-1,993.01,207.7 -165.0%   
INCOME DATA
Net Sales Rs m19,47732,985 59.0%  
Other income Rs m4071,170 34.8%   
Total revenues Rs m19,88434,155 58.2%   
Gross profit Rs m1,1035,245 21.0%  
Depreciation Rs m2,519162 1,556.0%   
Interest Rs m5,22738 13,682.7%   
Profit before tax Rs m-6,2366,215 -100.3%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,203 -5.7%   
Profit after tax Rs m-5,5804,012 -139.1%  
Gross profit margin %5.715.9 35.6%  
Effective tax rate %2.035.4 5.7%   
Net profit margin %-28.712.2 -235.5%  
BALANCE SHEET DATA
Current assets Rs m11,01422,655 48.6%   
Current liabilities Rs m32,0606,681 479.9%   
Net working cap to sales %-108.148.4 -223.1%  
Current ratio x0.33.4 10.1%  
Inventory Days Days9565 146.5%  
Debtors Days Days3429 115.1%  
Net fixed assets Rs m29,440835 3,523.8%   
Share capital Rs m705213 331.5%   
"Free" reserves Rs m2,04316,715 12.2%   
Net worth Rs m3,80016,928 22.4%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51024,162 192.5%  
Interest coverage x-0.2163.7 -0.1%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.41.4 30.7%   
Return on assets %-0.816.8 -4.5%  
Return on equity %-146.923.7 -619.6%  
Return on capital %-3.736.9 -10.1%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,513369 2,038.7%   
Fx outflow Rs m5,6493,807 148.4%   
Net fx Rs m1,865-3,438 -54.2%   
CASH FLOW
From Operations Rs m1,6821,527 110.1%  
From Investments Rs m-9,860-2,148 459.0%  
From Financial Activity Rs m6,644-1,024 -648.6%  
Net Cashflow Rs m-1,535-1,646 93.3%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 7.9 58.2%  
FIIs % 3.3 0.1 3,300.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.1 323.4%  
Shareholders   84,811 18,270 464.2%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  AJANTA PHARMA  UNICHEM LAB  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Dec 7, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS